Literature DB >> 9395747

Portal Hypertensive gastropathy.

J M Piqué1.   

Abstract

The term portal hypertensive gastropathy (PHG) defines a wide spectrum of diffuse macroscopic lesions that appear in the gastric mucosa of patients with portal hypertension. Histologically, these lesions correspond to dilated vessels in the mucosa and submucosa in the absence of erosions or inflammation. Endoscopically, the lesions are classified as mild when mosaic pattern or superficial reddening are present, and severe when gastric mucosa appear with diffuse cherry red spots. Mild lesions are highly prevalent (65-90%), whereas severe lesions are present in only 10-25% of cirrhotic patients. The pathogenesis of PHG is not well known, but both venous congestion related with raised portal pressure and increased gastric blood flow seem to be crucial factors for its development. Variceal sclerosis may contribute to the development or aggravation of the lesions. Bleeding is the unique clinical manifestation of PHG, and occurs only in those patients with severe lesions. During a 5-year follow-up, the risk of overt bleeding or chronic bleeding, which induces anaemia, is 60 % and 90%, respectively, for patients with severe PHG. Propranolol is the only pharmacological treatment that has been proven useful in preventing bleeding from PHG. Porto-systemic shunts and liver transplantation are also effective.

Entities:  

Mesh:

Year:  1997        PMID: 9395747     DOI: 10.1016/s0950-3528(97)90039-7

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  7 in total

Review 1.  Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.

Authors:  K W Burak; S S Lee; P L Beck
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 2.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

3.  Gastric mucosal resistance to acute injury in experimental portal hypertension.

Authors:  S Calatayud; M C Ramírez; M J Sanz; L Moreno; C Hernández; J Bosch; J M Piqué; J V Esplugues
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia.

Authors:  Nelson Garcia; Arun J. Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

Review 5.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Portal hypertensive gastropathy and gastric antral vascular ectasia.

Authors:  Hitendra Garg; Subhash Gupta; A C Anand; S L Broor
Journal:  Indian J Gastroenterol       Date:  2015-11-13

7.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.